Does timing of blood pressure med matter for kidney protection? new trial investigates

NCT ID NCT07259512

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 4 trial tests whether taking ramipril once daily or split into two smaller doses works better for protecting kidney function in 80 adults with chronic kidney disease and heart failure. Over 30 days, researchers will measure changes in blood markers of kidney function, inflammation, and oxidative stress. The goal is to find the best dosing schedule to slow kidney decline in this high-risk group.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Ramipril (an ACE inhibitor)
What this could lead to
If successful, this study could show that splitting the ramipril dose improves kidney protection in patients with both chronic kidney disease and heart failure.
What could go wrong
This is a small, short-term trial (80 patients, 30 days) looking at biomarkers, not long-term outcomes. Results may not translate to better kidney or heart health over time.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • UNS Hospital

    RECRUITING

    Kartasura, Central Java, Indonesia

More trials for these conditions

Other studies related to the condition(s) this trial covers.